Loading...
Incidence and Description of Autoimmune Cytopenias During Treatment with Ibrutinib for Chronic Lymphocytic Leukemia Autoimmune Cytopenias During Ibrutinib Treatment
Chronic lymphocytic leukemia (CLL) is frequently complicated by secondary autoimmune cytopenias (AIC). Ibrutinib is an irreversible inhibitor of Bruton’s Tyrosine Kinase approved for treatment of relapsed CLL and CLL with del(17p). The effect of ibrutinib treatment on the incidence of AIC is current...
Saved in:
| Published in: | Leukemia |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2015
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4986508/ https://ncbi.nlm.nih.gov/pubmed/26442611 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.273 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|